103.71
-0.14 (-0.14%)
| Previous Close | 103.85 |
| Open | 104.29 |
| Volume | 3,635,165 |
| Avg. Volume (3M) | 8,600,037 |
| Market Cap | 153,665,060,864 |
| Price / Earnings (TTM) | 55.46 |
| Price / Earnings (Forward) | 28.49 |
| Price / Sales | 7.76 |
| Price / Book | 6.36 |
| 52 Weeks Range | |
| Earnings Date | 22 Oct 2025 |
| Profit Margin | 11.58% |
| Operating Margin (TTM) | 20.09% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 20.90% |
| Quarterly Earnings Growth (YOY) | 36.20% |
| Total Debt/Equity (MRQ) | 52.16% |
| Current Ratio (MRQ) | 1.45 |
| Operating Cash Flow (TTM) | 3.81 B |
| Levered Free Cash Flow (TTM) | 2.32 B |
| Return on Assets (TTM) | 5.28% |
| Return on Equity (TTM) | 9.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Boston Scientific Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Large Core |
| % Held by Insiders | 0.18% |
| % Held by Institutions | 93.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bollard Group Llc | 30 Jun 2025 | 20,079,443 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 140.00 (UBS, 35.00%) | Buy |
| Median | 128.00 (23.43%) | |
| Low | 110.00 (Evercore ISI Group, 6.07%) | Buy |
| Average | 127.85 (23.28%) | |
| Total | 13 Buy | |
| Avg. Price @ Call | 100.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 23 Oct 2025 | 132.00 (27.28%) | Buy | 102.39 |
| 01 Oct 2025 | 132.00 (27.28%) | Buy | 95.85 | |
| Morgan Stanley | 23 Oct 2025 | 130.00 (25.36%) | Buy | 102.39 |
| Truist Securities | 23 Oct 2025 | 130.00 (25.36%) | Buy | 102.39 |
| 01 Oct 2025 | 129.00 (24.39%) | Buy | 95.85 | |
| UBS | 23 Oct 2025 | 140.00 (35.00%) | Buy | 102.39 |
| Wells Fargo | 23 Oct 2025 | 125.00 (20.53%) | Buy | 102.39 |
| BTIG | 22 Oct 2025 | 132.00 (27.28%) | Buy | 103.85 |
| 01 Oct 2025 | 132.00 (27.28%) | Buy | 95.85 | |
| Needham | 17 Oct 2025 | 121.00 (16.68%) | Buy | 99.24 |
| 01 Oct 2025 | 121.00 (16.68%) | Buy | 95.85 | |
| Evercore ISI Group | 07 Oct 2025 | 110.00 (6.07%) | Buy | 95.90 |
| Barclays | 02 Oct 2025 | 136.00 (31.14%) | Buy | 96.22 |
| Baird | 01 Oct 2025 | 128.00 (23.43%) | Buy | 95.85 |
| Leerink Partners | 01 Oct 2025 | 128.00 (23.43%) | Buy | 95.85 |
| RBC Capital | 29 Sep 2025 | 125.00 (20.53%) | Buy | 97.04 |
| Oppenheimer | 08 Sep 2025 | 125.00 (20.53%) | Buy | 108.14 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Oct 2025 | Announcement | Boston Scientific announces results for third quarter 2025 |
| 17 Oct 2025 | Announcement | Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc. |
| 01 Oct 2025 | Announcement | Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million |
| 09 Sep 2025 | Announcement | Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million |
| 02 Sep 2025 | Announcement | Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results |
| 05 Aug 2025 | Announcement | CMCT Announces 30,821-Square-Foot Lease to Boston Scientific Corporation at Penn Field, a 228,000-Square-Foot Creative Office Campus in Austin |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |